Document Detail


The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
MedLine Citation:
PMID:  23036238     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The introduction of anti- tumor necrosis factor-alpha agents (TNF-inhibitors) offered new dimensions in symptom relief and alteration of disease progression for patients with Ankylosing Spondylitis (AS). In 2007, Infliximab, Etanercept and Adalimumab were approved for AS in Austria. Drug reimbursement data of 2007 were retrieved to evaluate frequency of prescription, preferred substance and data on switching therapies.
METHODS: Data from eight health insurance funds covering 5.4 million insured people, which corresponds to 64% of the population, was analyzed by linking two databases, combining data on therapy of individual patients and their diagnosis. For those patients on TNF-inhibitors in 2007 reimbursement data from 2008 and 2009 were obtained, respectively.
RESULTS: A total of 694 patients with AS on TNF inhibitors in 2007 were identified for data analysis. Yearly costs for TNF-inhibitors were highest for Adalimumab (14,399 € per patient) followed by Infliximab (11,685 € per patient) and Etanercept (10,184 € per patient). In first-time TNF-inhibitor prescriptions, Adalimumab was prescribed most often, with a tendency towards prescription of Adalimumab and Etanercept in the younger and Infliximab in the older population. In the first year of prescription, 12% of patients already switched from the initially prescribed drug to another substance with those started on Etanercept showing the lowest switching rate. One-year drug survival in our data was highest for Etanercept with 83% still on the drug after 1 year, followed by Infliximab and then Adalimumab, while two-year drug survival was also highest for Etanercept (58%), followed by Adalimumab and then Infliximab.
CONCLUSIONS: Patients with Ankylosing Spondylitis starting on TNF-inhibiting therapy in Austria in 2007 were treated most often with Adalimumab, while Etanercept showed the lowest switching rate and the longest 1- and 2-year drug survival.
Authors:
Valerie Nell-Duxneuner; Yvonne Schroeder; Berthold Reichardt; Anna Bucsics
Related Documents :
21427578 - Drug-free remission: is it already possible?
24991628 - Drug-related problems among medical ward patients in jimma university specialized hospi...
24475918 - Drug delivery to the back of the eye following topical administration: an update on res...
24958968 - Flutamide: hirsutism in women.
11078818 - Drug development with hints from traditional indian ayurveda medicine: hepatitis and rh...
9131198 - Drugs for amnesia in the icu.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  50     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-23     Completed Date:  2013-04-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  867-72     Citation Subset:  IM    
Affiliation:
Department for Rheumatology, Heinrich Collin Strasse, Wien, Austria. valerie.nell-duxneuner@osteologie.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Australia
Drug Costs
Female
Humans
Immunoglobulin G / therapeutic use
Male
Middle Aged
Receptors, Tumor Necrosis Factor / therapeutic use
Retrospective Studies
Spondylitis, Ankylosing / drug therapy*
Time Factors
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of contraindicated drugs in patients with chronic liver disease: a therapeutic dilemma.
Next Document:  Hypertonic saline reduces lipopolysaccharide-induced mouse brain edema through inhibiting aquaporin ...